Literature DB >> 15569932

Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development.

Ming Yan1, Sebastien A Burel, Luke F Peterson, Eiki Kanbe, Hiromi Iwasaki, Anita Boyapati, Robert Hines, Koichi Akashi, Dong-Er Zhang.   

Abstract

Normal blood-cell differentiation is controlled by regulated gene expression and signal transduction. Transcription deregulation due to chromosomal translocation is a common theme in hematopoietic neoplasms. AML1-ETO, which is a fusion protein generated by the 8;21 translocation that is commonly associated with the development of acute myeloid leukemia, fuses the AML1 runx family DNA-binding transcription factor to the ETO corepressor that associates with histone deacetylase complexes. Analyses have demonstrated that AML1-ETO blocks AML1 function and requires additional mutagenic events to promote leukemia. Here, we report that the loss of the molecular events of AML1-ETO C-terminal NCoR/SMRT-interacting domain transforms AML1-ETO into a potent leukemogenic protein. Contrary to full-length AML1-ETO, the truncated form promotes in vitro growth and does not obstruct the cell-cycle machinery. These observations suggest a previously uncharacterized mechanism of tumorigenesis, in which secondary mutation(s) in molecular events disrupting the function of a domain of the oncogene promote the development of malignancy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15569932      PMCID: PMC535382          DOI: 10.1073/pnas.0406702101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  A clonogenic common myeloid progenitor that gives rise to all myeloid lineages.

Authors:  K Akashi; D Traver; T Miyamoto; I L Weissman
Journal:  Nature       Date:  2000-03-09       Impact factor: 49.962

2.  A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia.

Authors:  B Lutterbach; J J Westendorf; B Linggi; S Isaac; E Seto; S W Hiebert
Journal:  J Biol Chem       Date:  2000-01-07       Impact factor: 5.157

Review 3.  AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia.

Authors:  G Nucifora; J D Rowley
Journal:  Blood       Date:  1995-07-01       Impact factor: 22.113

4.  The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses.

Authors:  R K Naviaux; E Costanzi; M Haas; I M Verma
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

5.  Identification of two transcripts of AML1/ETO-fused gene in t(8;21) leukemic cells and expression of wild-type ETO gene in hematopoietic cells.

Authors:  T Era; N Asou; T Kunisada; H Yamasaki; H Asou; N Kamada; S Nishikawa; K Yamaguchi; K Takatsuki
Journal:  Genes Chromosomes Cancer       Date:  1995-05       Impact factor: 5.006

6.  Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction.

Authors:  T Kozu; H Miyoshi; K Shimizu; N Maseki; Y Kaneko; H Asou; N Kamada; M Ohki
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

7.  Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells.

Authors:  P E Nisson; P C Watkins; N Sacchi
Journal:  Cancer Genet Cytogenet       Date:  1992-10-15

8.  Alternative, out-of-frame runt/MTG8 transcripts are encoded by the derivative (8) chromosome in the t(8;21) of acute myeloid leukemia M2.

Authors:  J E Tighe; F Calabi
Journal:  Blood       Date:  1994-10-01       Impact factor: 22.113

9.  Molecular diversity in AML1/ETO fusion transcripts in patients with t(8;21) positive acute myeloid leukaemia.

Authors:  L T van de Locht; T F Smetsers; S Wittebol; R A Raymakers; E J Mensink
Journal:  Leukemia       Date:  1994-10       Impact factor: 11.528

10.  The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript.

Authors:  H Miyoshi; T Kozu; K Shimizu; K Enomoto; N Maseki; Y Kaneko; N Kamada; M Ohki
Journal:  EMBO J       Date:  1993-07       Impact factor: 11.598

View more
  59 in total

1.  RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1).

Authors:  R Katherine Hyde; P Paul Liu
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

Review 2.  Fusion-protein truncation provides new insights into leukemogenesis.

Authors:  Jay L Hess; Bruce A Hug
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-30       Impact factor: 11.205

3.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

4.  Multivalent binding of the ETO corepressor to E proteins facilitates dual repression controls targeting chromatin and the basal transcription machinery.

Authors:  Chun Guo; Qiande Hu; Chunxia Yan; Jinsong Zhang
Journal:  Mol Cell Biol       Date:  2009-03-16       Impact factor: 4.272

Review 5.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

6.  Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1.

Authors:  Yasuhiko Kamikubo; Ling Zhao; Mark Wunderlich; Takeshi Corpora; R Katherine Hyde; Thomas A Paul; Mondira Kundu; Lisa Garrett; Sheila Compton; Gang Huang; Linda Wolff; Yoshiaki Ito; John Bushweller; James C Mulloy; P Paul Liu
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

7.  CBFbeta is critical for AML1-ETO and TEL-AML1 activity.

Authors:  Liya Roudaia; Matthew D Cheney; Ekaterina Manuylova; Wei Chen; Michelle Morrow; Sangho Park; Chung-Tsai Lee; Prabhjot Kaur; Owen Williams; John H Bushweller; Nancy A Speck
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

Review 8.  Runx1/AML1 in normal and abnormal hematopoiesis.

Authors:  Tetsuya Yamagata; Kazuhiro Maki; Kinuko Mitani
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

9.  Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.

Authors:  Eun-Young Ahn; Ming Yan; Oxana A Malakhova; Miao-Chia Lo; Anita Boyapati; Hans Beier Ommen; Robert Hines; Peter Hokland; Dong-Er Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-24       Impact factor: 11.205

10.  Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.

Authors:  Russell C DeKelver; Ming Yan; Eun-Young Ahn; Wei-Jong Shia; Nancy A Speck; Dong-Er Zhang
Journal:  Blood       Date:  2013-02-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.